EMPA-REG OUTCOME: The Nephrologist's Point of View

American Journal of Medicine

Volumn 130, Issue 6, 2017, Pages S63-S72

  Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Canagliflozin; Dapagliflozin; Empagliflozin; Renal outcomes; Renoprotection; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CARDIOVASCULAR FUNCTION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG MECHANISM; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; NEPHROLOGIST; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RENAL PROTECTION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; KIDNEY; METABOLISM; RISK FACTOR;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020107839     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.04.007     Document Type: Article

References (61)

1. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
2. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
3. Packham, D.K., Wolfe, R., Reutens, A.T., et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23 (2012), 123–130.
4. de Zeeuw, D., Akizawa, T., Audhya, P., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369 (2013), 2492–2503.
5. Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
6. Fernandez Juarez, G., Luño, J., Barrio, V., et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis 61 (2013), 211–218.
7. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
8. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
9. International Diabetes Federation. Diabetes Atlas 2015. Available at: http://www.diabetesatlas.org/ Accessed October 12, 2016.
10. Corriere, M., Rooparinesingh, N., Kalyani, R.R., Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep 13:6 (2013), 805–813.
11. Dieter, B.P., Alicic, R.Z., Meek, R.L., Anderberg, R.J., Cooney, S.K., Tuttle, K.R., Novel therapies for diabetic kidney disease: storied past and forward paths. Diabetes Spectr 28 (2015), 167–174.
12. Alegre-Díaz, J., Herrington, W., López-Cervantes, M., et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 375 (2016), 1961–1971.
13. Mora-Fernández, C., Domínguez-Pimentel, V., de Fuentes, M.M., Górriz, J.L., Martínez-Castelao, A., Navarro-González, J.F., Diabetic kidney disease: from physiology to therapeutics. J Physiol 592 (2014), 3997–4012.
14. Toth-Manikowski, S., Atta, M.G., Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res, 2015, 2015, 697010.
15. Abdul-Ghani, M.A., DeFronzo, R.A., Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14 (2008), 782–790.
16. DeFronzo, R.A., Davidson, J.A., Del Prato, S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
17. Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
18. Abdul-Ghani, M.A., Defronzo, R.A., Norton, L., Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62 (2013), 3324–3328.
19. Vallon, V., Thomson, S.C., Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60 (2017), 215–225.
20. Thrasher, J., Management of type 2 diabetes: available therapies. Am J Med 130:suppl 6 (2017), S4–S17.
21. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
22. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
23. Altemtam, N., Russell, J., El Nahas, M., A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant 27 (2012), 1847–1854.
24. Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
25. Ridderstråle, M., Andersen, K.R., Zeller, C., Kim, G., Woerle, H.J., Broedl, U.C., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
26. Cefalu, W.T., Leiter, L.A., Yoon, K.H., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 (2013), 941–950.
27. Heerspink, H.J., Desai, M., Jardine, M., Balis, D., Meininger, G., Perkovic, V., Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
28. Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
29. Fioretto, P., Stefansson, B.V., Johnsson, E., Cain, V.A., Sjöström, C.D., Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59 (2016), 2036–2039.
30. de Boer, I.H., Kahn, S.E., SGLT2 inhibitors - sweet success for diabetic kidney disease?. J Am Soc Nephrol 28 (2017), 7–10.
31. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
32. Vallon, V., Gerasimova, M., Rose, M.A., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306 (2014), F194–F204.
33. Škrtić, M., Yang, G.K., Perkins, B.A., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57 (2014), 2599–2602.
34. Heerspink, H.J., Kröpelin, T.F., Hoekman, J., de Zeeuw, D., Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
35. Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
36. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
37. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86 (2014), 1057–1058.
38. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
39. Odden, M.C., Amadu, A.R., Smit, E., Lo, L., Peralta, C.A., Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis 64 (2014), 550–557.
40. Kanji, T., Gandhi, M., Clase, C.M., Yang, R., Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol, 16, 2015, 58.
41. Johnson, R.J., Nakagawa, T., Jalal, D., Sánchez-Lozada, L.G., Kang, D.H., Ritz, E., Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant 28 (2013), 2221–2228.
42. Ceriello, A., Genovese, S., Mannucci, E., Gronda, E., Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol, 15, 2016, 123.
43. Farah, A.E., Glucagon and the circulation. Pharmacol Rev 35 (1983), 181–217.
44. Bankir, L., Roussel, R., Bouby, N., Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. Am J Physiol Renal Physiol 309 (2015), F2–F23.
45. Ferrannini, E., Muscelli, E., Frascerra, S., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
46. Haase, V.H., Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291 (2006), F271–F281.
47. Chang, Y.K., Choi, H., Jeong, J.Y., et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 11, 2016, e0158810.
48. US Food and Drug Administration. Drug safety communication (June 14, 2016): FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm Accessed June 22, 2016.
49. ® (dapagliflozin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s011lbl.pdf Accessed March 22, 2017.
50. ® (canagliflozin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s022lbl.pdf Accessed December 6, 2016.
51. ® (empagliflozin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf Accessed December 6, 2016.
52. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15 (2013), 463–473.
53. Yamout, H., Perkovic, V., Davies, M., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 40 (2014), 64–74.
54. Kohan, D.E., Fioretto, P., Johnsson, K., Parikh, S., Ptaszynska, A., Ying, L., The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 29 (2016), 391–400.
55. Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
56. Janssen-Cilag International NV. Summary of product characteristics: Invokana 100 mg and 300 mg film-coated tablets. Available at: http://www.ema.europa.eu/ema/ Accessed November 29, 2016.
57. AstraZeneca AB. Summary of product characteristics: Forxiga 5 mg and 10 mg film-coated tablets. Available at: http://www.ema.europa.eu/ema/ Accessed November 29, 2016.
58. Boehringer Ingelheim International GmbH. Summary of product characteristics: Jardiance 10 mg and 25 mg film-coated tablets. Available at: http://www.ema.europa.eu/ema/ Accessed November 29, 2016.
59. CREDENCE. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02065791 Accessed October 14, 2016.
60. CANVAS-R. A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R). Available at: https://clinicaltrials.gov/ct2/show/study/NCT01989754 Accessed October 14, 2016.
61. AstraZeneca. A study to evaluate the effect of dapagliflozin with and without saxagliptin on albuminuria, and to investigate the effect of dapagliflozin and saxagliptin on HbA1c in patients with type 2 diabetes and CKD3. Available at: https://clinicaltrials.gov/ct2/show/NCT02547935 Accessed November 17, 2016.